PulseAugur
EN
LIVE 15:34:41
中文(ZH) ST万邦：WP107药品多剂量爬坡临床研究获得美国FDA许可

ST Wanbang's Myasthenia Gravis Drug WP107 Gains FDA Approval for Clinical Trials

By PulseAugur Editorial · [1 sources] ·

ST Wanbang's subsidiary, Wanbangde Pharmaceutical Group, has received approval from the U.S. Food and Drug Administration (FDA) to conduct a multi-dose dose-climbing clinical trial for its new drug, WP107. This drug is an oral solution of Huperzine A and is intended for the treatment of generalized myasthenia gravis. The approval allows for studies in healthy trial participants. AI

RANK_REASON The item describes regulatory approval for a new drug's clinical trial, which falls under research and policy. [lever_c_demoted from research: ic=1 ai=0.4]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

ST Wanbang's Myasthenia Gravis Drug WP107 Gains FDA Approval for Clinical Trials

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
The item describes regulatory approval for a new drug's clinical trial, which falls under research and policy. [lever_c_demoted from research: ic=1 ai=0.4]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, policy
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Standard
On-topic for AI-industry coverage; kept in the public index.
Story freshness
59 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    ST Wanbang: WP107 Drug Multi-dose Escalation Clinical Study Receives US FDA Approval

    36氪获悉，ST万邦公告，公司全资子公司万邦德制药集团有限公司自主研发用于全身型重症肌无力治疗的新药WP107（石杉碱甲口服溶液），于近期获得美国食品药品监督管理局（简称“FDA”）批准本品用于健康试验参与者的多剂量爬坡临床试验研究。

RELATED ENTITIES

RELATED TOPICS